One-third of patients give up on DOACs after six months
As many as one in three patients stop taking direct-acting oral anticoagulants (DOACs) soon after being prescribed them, researchers have found.
In findings that suggest the real-world impact of DOACs may be less than seen in clinical trials, a Canadian study of 26,000 patients treated with the drugs found that 36% of dabigatran users and 32% of rivaroxaban users were ‘non-persistent’ within six months of initiation.
Patients who stopped their DOAC therapy for at least two weeks had a 4-6-fold higher risk of stroke or TIA. Patients who did not persist with DOACs also had an 80%